Furthermore, MS@MOF cancer vaccines, in combination with systemic checkpoint blockade at merely 10% dose of PD-1 blockade monotherapy9,11,25, exhibit synergetic effects that reverse the immunosuppressive tumour microenvironment, elicit robust adaptive cancer antigen-specific immune responses, and effectively induce durable tumour suppression in tumour-bearing mice. This evidence concerns the gene PDCD1 and neoplasm.